Apogee Biotechnology

Apogee Biotechnology Corporation is dedicated to developing its sphingosine kinase inhibitor program for the treatment of solid tumors, various chronic inflammatory diseases, and acute destructive inflammation indications. Their pipeline includes small molecule inhibitors of sphingosine kinase. Sphingosine kinase produces sphingosine-1-phosphate, which drives many types of cancers, inflammatory diseases, and disorders. Their primary disease focus is utilizing their technology to treat solid tumors, which have been validated in preclinical animal tumor models, including renal cell carcinoma, breast cancer, brain cancer, pancreatic cancer, myeloma, and colon cancer.